Sugi Predict

Sugi Predict / Compounds / SCHEMBL553834

SCHEMBL553834

SCHEMBL553834

CCn1cc(C(=O)O)cn1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 1/20 0.73
▸ LMNA P02545 4/20 0.50
▸ MAPT P10636 4/20 0.50
▸ CYP2C19 P33261 1/20 0.50
▸ GFER P55789 1/20 0.50
▸ NPSR1 Q6W5P4 1/20 0.50
▸ HPGD P15428 2/20 0.48
▸ ALKBH2 Q6NS38 2/20 0.46
▸ HPGDS O60760 1/20 0.46
▸ TSHR P16473 1/20 0.45
▸ PLA2G4A P47712 1/20 0.44
▸ ALDH1A1 P00352 3/20 0.44
▸ KDM4E B2RXH2 2/20 0.44
▸ KMT2A Q03164 2/20 0.44
▸ ACHE P22303 2/20 0.44
▸ HSD17B10 Q99714 1/20 0.44
▸ PKM P14618 1/20 0.43
▸ PROKR1 Q8TCW9 1/20 0.42
▸ TDP1 Q9NUW8 1/20 0.40
▸ ALKBH1 Q13686 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL4758885 0.98 L3MBTL1 (0.71) L3MBTL1LMNAMAPTCYP2C19GFER
Pyridine SCHEMBL27711018 0.87 L3MBTL1 (0.58) L3MBTL1LMNAMAPTCYP2C19GFER
SCHEMBL31286462 0.85 L3MBTL1 (0.69) L3MBTL1LMNAMAPTCYP2C19GFER
SCHEMBL4240582 0.85 L3MBTL1 (1.00) L3MBTL1LMNAMAPTCYP2C19GFER
SCHEMBL3016241 0.85 L3MBTL1 (0.54) L3MBTL1LMNAMAPTCYP2C19GFER
SCHEMBL12159798 0.84 L3MBTL1 (0.53) L3MBTL1LMNAMAPTCYP2C19GFER
SCHEMBL31681673 0.83 L3MBTL1 (0.67) L3MBTL1ALKBH2HPGDSPLA2G4AACHE
SCHEMBL3063805 0.82 L3MBTL1 (0.51) L3MBTL1LMNAMAPTCYP2C19GFER
SCHEMBL13181146 0.82 L3MBTL1 (0.51) L3MBTL1LMNAMAPTCYP2C19GFER
SCHEMBL1001641 0.82 L3MBTL1 (0.51) L3MBTL1LMNAMAPTCYP2C19GFER

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 243 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111108109-A Substituted dihydrothienopyrimidines and their use as phosphodiesterase inhibitors 利奥制药有限公司 2020-05-05 — — CN claimed
EP-1899296-B1 HISTAMINE-3 RECEPTOR ANTAGONISTS PFIZER PROD INC (US) 2010-11-17 — — EP claimed
US-7812040-B2 such as 3-(3-Acetyl-phenyl)-1-[3-(3-chloro-4-pyrrolidin-1-ylmethyl-phenoxy)-cyclobutylmethyl]-1-methyl-urea, used for the treatment of , schizophrenia, Alzheimer's disease, attention-deficit hyperactivity disorder, hypotension, allergies, cardiovascular, gastrointestinal and psychological disorders PFIZER INC. (US) 2010-10-12 — — US claimed
US-20090131433-A1 HISTAMINE-3 RECEPTOR ANTAGONISTS PFIZER INC. (US) 2009-05-21 — — US claimed
EP-0743574-B1 Migration imaging members XEROX CORP (US) 2000-12-27 — — EP claimed
EP-0743573-B1 Method for obtaining image contrast migration imaging members XEROX CORP (US) 2000-09-06 — — EP claimed
EP-0673783-B1 Recording sheets containing purine, pyrimidine, benzimidazole, imidazolidine, urazole, pyrazole, triazole, benzotriazole, tetrazole, and pyrazine compounds XEROX CORP (US) 2000-07-05 — — EP claimed
EP-4029868-B1 MCL-1 INHIBITORS GILEAD SCIENCES INC (US) 2026-05-20 — — EP disclosed
EP-4737449-A1 P53-Y220C SELECTIVE SMALL-MOLECULAR REACTIVATOR COMPOUND, PHARMACEUTICAL COMPOSITION AND USE THEREOF Changchun Genescience Pharmaceutical Co., Ltd. (CN) 2026-05-06 — — EP disclosed
US-12600728-B2 Interleukin-17 inhibitors NOVARTIS AG (CH) 2026-04-14 — — US disclosed
WO-2025235957-A1 P53 MUTANT STABILIZER AND USES THEREOF FRONTIER MEDICINES CORPORATION (US) 2025-11-13 — — WO disclosed
US-20250236608-A1 EGFR INHIBITORS BLUEPRINT MEDICINES CORPORATION 2025-07-24 — — US disclosed
US-20250197421-A1 MCL1 INHIBITORS GILEAD SCIENCES, INC. 2025-06-19 — — US disclosed
EP-1389616-A1 NOVEL BENZYLPIPERIDINE COMPOUND Mitsubishi Pharma Corporation (JP) 2004-02-18 — — EP disclosed
CN-1474803-A Novel amide derivative and medical use thereof ������ҩ��ʽ���� 2004-02-11 — — CN disclosed
CN-1466569-A Novel 3-substituted urea derivatives and pharmaceutical use thereof ������ҩ��ʽ���� 2004-01-07 — — CN disclosed
US-20030207939-A1 Novel 3-substituted urea derivatives and medicinal use thereof MITSUBISHI PHARMA CORPORATION (JP) 2003-11-06 — — US disclosed
EP-1318140-A1 NOVEL AMIDE DERIVATIVES AND MEDICINAL USE THEREOF UGS Mitsubishi Pharma Corporation (JP) 2003-06-11 — — EP disclosed
EP-1308438-A1 3-SUBSTITUTED UREA DERIVATIVES AND MEDICINAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2003-05-07 — — EP disclosed
US-5310918-A 1-aryl-substituted azole, non-linear optical material and novel molecular crystal containing same and method and module for the conversion of light wavelength using same FUJI PHOTO FILM CO., LTD. (JP) 1994-05-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131433-A1 HISTAMINE-3 RECEPTOR ANTAGONISTS HRH3, HRH4, HRH2 L3MBTL1 4076/4885LMNA 4511/4885MAPT 320/4885
US-20030207939-A1 Novel 3-substituted urea derivatives and medicinal use thereof C5AR1, C5AR2, C3AR1 L3MBTL1 1480/4885LMNA 3941/4885MAPT 205/4885
US-20250236608-A1 EGFR INHIBITORS EGFR, ERBB2, ERBB3 L3MBTL1 4175/4885LMNA 4778/4885MAPT 2806/4885
US-20250197421-A1 MCL1 INHIBITORS MCL1, BCL2L1, BCLAF1 L3MBTL1 775/4885LMNA 1604/4885MAPT 3533/4885
US-12600728-B2 Interleukin-17 inhibitors IL17A, IL2, IL1B L3MBTL1 4278/4885LMNA 3977/4885MAPT 265/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.